VerbatimParliament, as it happens

Prostate Cancer: Screening

Asked by Jim ShannonDemocratic Unionist PartyDepartment of Health and Social CareTabled Answered 14 January 2026UIN 100314

The question

To ask the Secretary of State for Health and Social Care, what assessment he has been made of the adequacy of national production capacity for PSMA radiotracers in the context of projected clinical demand for prostate cancer diagnosis.

Answered by Ashley Dalton

Prostate-specific membrane antigen (PSMA) radiotracers are commissioned for use as part of PET-CT prostate cancer imaging, as set out in the published clinical commissioning policy. Access to PET-CT, as with any healthcare service, is closely monitored.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim